Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from 60 Degrees Pharmaceuticals, Inc. ( (SXTP) ) is now available.
On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. presented investor information highlighting the potential growth of ARAKODA, especially for chronic babesiosis, which could surpass its use for malaria prevention. The company faces challenges such as low brand recognition and competition from generic alternatives, but aims to address these through a commercial pilot program to increase awareness and differentiate ARAKODA in the market.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Underperform.
SXTP’s overall stock score is weighed down by poor financial performance and weak technical indicators. While the recent capital injection is a positive development, significant challenges in profitability and valuation remain.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of treatments for malaria and babesiosis. Their primary products include Tafenoquine (ARAKODA) and Celgosivir/Australian Chestnut extracts, with a market cap of $5.8 million.
Average Trading Volume: 571,323
Technical Sentiment Signal: Sell
Current Market Cap: $5.79M
Learn more about SXTP stock on TipRanks’ Stock Analysis page.